<DOC>
	<DOCNO>NCT01203358</DOCNO>
	<brief_summary>The purpose study compare efficacy two surfactant , Exosurf Neonatal ( Burroughs Wellcome Co. ) Survanta ( Ross Laboratories ) , treatment neonatal respiratory distress syndrome .</brief_summary>
	<brief_title>Exosurf Neonatal Survanta Treatment Respiratory Distress Syndrome</brief_title>
	<detailed_description>The NICHD Neonatal Research Network conduct randomize trial 11 center compare efficacy two surfactant -- Exosurf Neonatal ( Burroughs Wellcome Co. ) Survanta ( Ross Laboratories ) -- treatment neonatal respiratory distress syndrome . Newborn infant birth weight 501-1500g respiratory distress syndrome receiving assist ventilation 30 % oxygen within 6 hour birth enrol January 1991 January 1992 . Infants randomly assign receive four intratracheal dose either Exosurf Neonatal Survanta .</detailed_description>
	<mesh_term>Respiratory Distress Syndrome , Newborn</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Adult</mesh_term>
	<mesh_term>Birth Weight</mesh_term>
	<mesh_term>Bronchopulmonary Dysplasia</mesh_term>
	<mesh_term>Pulmonary Surfactants</mesh_term>
	<mesh_term>Beractant</mesh_term>
	<criteria>Newborn infant weigh 501 1500 gm respiratory distress syndrome receiving assist ventilation 30 % oxygen Less 6 hour age</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>6 Hours</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>NICHD Neonatal Research Network</keyword>
	<keyword>Extremely Low Birth Weight ( ELBW )</keyword>
	<keyword>Prematurity</keyword>
	<keyword>Respiratory distress syndrome</keyword>
	<keyword>Surfactant</keyword>
</DOC>